Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania

Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania

(2011) Sabina F Mugusi et al.   ANTIVIRAL THERAPY

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

(2011) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug-induced liver injury: a summary of recent advances

(2011) Jonathan G Stine et al.   Expert Opinion on Drug Metabolism & Toxicology

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

(2011) A. Habtewold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia

(2011) Elixabet Lopez-Lopez et al.   PEDIATRIC BLOOD & CANCER

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients

(2011) Getnet Yimer et al.   PLoS One

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of drug-induced liver injury

(2010) Stefan Russmann et al.   HEPATOLOGY

Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda

(2010) P Ocama et al.   INTERNATIONAL JOURNAL OF STD & AIDS

The Convergence of Therapeutic Drug Monitoring and Pharmacogenetic Testing to Optimize Efavirenz Therapy

(2010) Salvador Cabrera Figueroa et al.   THERAPEUTIC DRUG MONITORING

Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients

(2010) Alma Tostmann et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Development of fatal acute liver failure in HIV-HBV coinfected patients

(2010) Albert M Anderson   WORLD JOURNAL OF GASTROENTEROLOGY

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

(2010) Verena Gounden et al.   AIDS Research and Therapy

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events

(2009) Christopher J Hoffmann et al.   AIDS

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

(2009) Jackson K. Mukonzo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation

(2009) A. Turkova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Verbal autopsy can consistently measure AIDS mortality: a validation study in Tanzania and Zimbabwe

(2009) B Lopman et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

Management of individuals requiring antiretroviral therapy and TB treatment

(2009) Karen Cohen et al.   Current Opinion in HIV and AIDS

Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients

(2008) Getnet Yimer et al.   PLoS One

Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review

(2007) Alma Tostmann et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY